MedPath

Comparision between two uterotonics : Carbetocin versus Oxytoci

Phase 3
Conditions
Health Condition 1: O722- Delayed and secondary postpartum hemorrhage
Registration Number
CTRI/2023/09/057571
Lead Sponsor
Datta Meghe Institute of Higher Education and Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Consenting, healthy pregnant women, with singleton pregnancy, undergoing elective caesarean section at term with regional anesthesia.

Exclusion Criteria

Women with placenta previa, placental abruption, and multiple gestation as these conditions are associated with an increased risk of PPH. Women with pregnancy-related complications and disorders such as pre-eclampsia, gestational diabetes, or pre-existing diseases such as insulin-dependent diabetes, cardiovascular or renal diseases, or hypo-/hyperthyroidism (these conditions could possibly interfere with hemodynamic parameters). Women taking medication with a known impact on the cardiovascular system. Women undergoing caesarean section with general anesthesia were also excluded, as carbetocin is licensed for use only with regional anesthesia.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Effects of both drugs on maternal heart rate (HR) and blood pressure (BP).Timepoint: 1 hour (starting from drug administration till one hour thereon).
Secondary Outcome Measures
NameTimeMethod
The impact of both drugs on post operative blood loss, and need of additional uterotonics, and changes in post operative hemoglobin and uterine tone.Timepoint: Post operative 1 hour
© Copyright 2025. All Rights Reserved by MedPath